COVID-19 taskforce publishes new risk classification tool
Monday, 21 March, 2022
The has developed a to guide clinicians making decisions about which people are most likely to benefit from drug treatments.
While the available evidence is not sufficient to enable the Taskforce to determine which individual patients are most likely to benefit from treatment, the recommended drugs are likely to be most effective in preventing severe illness and mortality in those people who are at highest risk of these outcomes.
The risk of developing severe illness is higher in Aboriginal and Torres Strait Islander people due to inequity arising from social determinants of health.
The examples in the matrix are based on the clinical expertise of the Taskforce and are not definitive nor exhaustive. Clinicians should also consider whether people are unlikely to be able to access higher level care due to geographical remoteness or other factors. Feedback for the tool can be sent to .
Victoria's Q3 median ED wait times the lowest on record
Victoria's quarter three performance data (January–March) has shown improvement across...
Irregularities in a clinician's cases prompt 15-month lookback
St Vincent's ºÚÁϳԹÏÈºÍø Sydney has detailed a 15-month lookback review — prompted by...
Two researchers receive $899,000 in cardiovascular funding
In heart-related news this Heart Week (5–11 May), two University of Newcastle researchers...